ProShare Advisors
XBIT icon

ProShare Advisors’s XBiotech XBIT Stock Holding History

ProShare Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,456
Closed -$214K – 1610
2019
Q4 		$214K Buy
+11,456
New +$148K ﹤0.01% 1544
2017
Q4 		– Sell
-21,275
Closed -$93K – 1805
2017
Q3 		$93K Buy
21,275
+1,452
+7% +$6.86K ﹤0.01% 1331
2017
Q2 		$93K Buy
19,823
+485
+3% +$4.65K ﹤0.01% 1402
2017
Q1 		$319K Sell
19,338
-4,918
-20% -$64.4K ﹤0.01% 1212
2016
Q4 		$245K Buy
24,256
+2,069
+9% +$27.5K ﹤0.01% 1494
2016
Q3 		$299K Sell
22,187
-4,034
-15% -$59.2K ﹤0.01% 1155
2016
Q2 		$549K Buy
26,221
+1,909
+8% +$27.6K 0.01% 928
2016
Q1 		$230K Sell
24,312
-2,156
-8% -$17.9K ﹤0.01% 1342
2015
Q4 		$288K Buy
+26,468
New +$338K ﹤0.01% 1308

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

ProShare Advisors's XBIT Position: Q1 2020 in Review

ProShare Advisors sold out of XBiotech (XBIT) in Q1 2020, closing a stake of 11,456 shares — an estimated $214K sold.

ProShare Advisors first reported a position in XBIT in Q4 2015 and held it in 9 quarters. The position peaked at $549K in Q2 2016. 60 funds tracked by Wall St. Rank hold XBIT as of Q1 2020.

  • ProShare Advisors reported no remaining XBiotech position as of Q1 2020 after selling out during the quarter.
  • ProShare Advisors sold 11,456 XBiotech shares in Q1 2020, an estimated $214K.
  • ProShare Advisors first reported a position in XBiotech in Q4 2015 and held it in 9 quarters.
  • ProShare Advisors's XBiotech position peaked at $549K in Q2 2016.
  • 60 funds tracked by Wall St. Rank held XBiotech as of Q1 2020.

Based on ProShare Advisors's 13F filing for Q1 2020, filed 15 May 2020.